William D Travis

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Oncol 1:S13-9. 2006
  2. ncbi International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 6:244-85. 2011
  3. ncbi Pulmonary Pathology Society Lifetime Achievement Award, 2007: Raymond Yesner, MD, professor of pathology emeritus, Yale University School of Medicine
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 131:1634. 2007
  4. ncbi The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 3:1213-23. 2008
  5. ncbi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Am Thorac Soc 8:381-5. 2011
  6. ncbi Pathology of lung cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Chest Med 32:669-92. 2011
  7. ncbi Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
    William D Travis
    Department of Pathology, Attending Thoracic Pathologist, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 25:S18-30. 2012
  8. ncbi Advances in neuroendocrine lung tumors
    W D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 21:vii65-71. 2010
  9. ncbi Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    J Thorac Oncol 3:1384-90. 2008
  10. ncbi Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Histopathology 54:3-11. 2009

Detail Information

Publications102 found, 100 shown here

  1. ncbi Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Oncol 1:S13-9. 2006
    ..Advances in the pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC) have demonstrated important new prognostic features that have led to changes in classification and diagnostic criteria...
  2. ncbi International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 6:244-85. 2011
    ....
  3. ncbi Pulmonary Pathology Society Lifetime Achievement Award, 2007: Raymond Yesner, MD, professor of pathology emeritus, Yale University School of Medicine
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 131:1634. 2007
  4. ncbi The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 3:1213-23. 2008
    ....
  5. ncbi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Am Thorac Soc 8:381-5. 2011
    ..The American Thoracic Society is a cosponsor of a newly published lung adenocarcinoma classification...
  6. ncbi Pathology of lung cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Chest Med 32:669-92. 2011
    ..Histologic criteria are also presented for other tumors...
  7. ncbi Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
    William D Travis
    Department of Pathology, Attending Thoracic Pathologist, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 25:S18-30. 2012
    ..Brief reference will be made to other neuroendocrine lung tumors with an overview of the molecular pathogenesis of this spectrum of tumors...
  8. ncbi Advances in neuroendocrine lung tumors
    W D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 21:vii65-71. 2010
    ..The diagnosis of SCLC, TC and AC can be made by light microscopy without the need for special tests in most cases, but for LCNEC it is required to demonstrate NE differentiation by immunohistochemistry or electron microscopy...
  9. ncbi Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    J Thorac Oncol 3:1384-90. 2008
    ..The elastic layer of the visceral pleura is not mentioned in the current International Union Against Cancer or American Joint Committee on Cancer staging documents...
  10. ncbi Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Histopathology 54:3-11. 2009
    ..TNM staging of carcinoid tumours and small cell carcinoma is also discussed...
  11. ncbi Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis
    Noriko Motoi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:810-27. 2008
    ..Such an approach should be considered in future studies for validation in other datasets...
  12. ncbi Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project
    William D Travis
    Attending Thoracic Pathologist, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Respir Crit Care Med 177:1338-47. 2008
    ..Concern was expressed that NSIP was a "wastebasket" category, difficult to distinguish from other idiopathic interstitial pneumonias...
  13. ncbi Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Respir Crit Care Med 32:22-31. 2011
    ..The need for every institution to develop a multidisciplinary strategy to obtain these small specimens and process them not only for diagnosis but also for molecular testing is emphasized...
  14. ncbi Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:3279-87. 2005
    ..To review recent advances in pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC)...
  15. ncbi Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases
    Nicolas Girard
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:1752-64. 2009
    ..Given its high correlation with molecular characterization of such tumors, it may provide a much cheaper and faster method to address this problem...
  16. ncbi Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
    Akihiko Yoshizawa
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mod Pathol 24:653-64. 2011
    ..The slightly stronger association with survival for invasive size versus gross size raises the need for further studies to determine whether this adjustment in measuring tumor size could impact TNM staging for small adenocarcinomas...
  17. ncbi Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
    ..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction...
  18. ncbi Comparison of patterns of relapse in thymic carcinoma and thymoma
    James Huang
    Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Cardiovasc Surg 138:26-31. 2009
    ..We reviewed our recent experience with the surgical management of thymic tumors and compared the outcomes and patterns of relapse between patients with thymic carcinoma and those with thymoma...
  19. ncbi Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Chest 137:46-52. 2010
    ..Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions...
  20. ncbi A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 25:1117-27. 2012
    ..005) after adjusting for clinical factors. We proposed this combined architectural/mitotic grade for lung adenocarcinoma as a practical method that can be applied in routine practice...
  21. ncbi High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1192-7. 2012
    ..We sought to investigate whether preoperative maximum standardized uptake value (SUVmax) on F-fluorodeoxyglucose (FDG) positron emission tomography (PET) correlates with histologic subtype in MPM...
  22. ncbi A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 25:260-71. 2012
    ..Nuclear grading in epithelioid mesothelioma provides a simple, practical, and cost-effective prognostic tool that better stratifies clinical outcome and time to recurrence than currently available clinicopathologic factors...
  23. ncbi Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  24. ncbi Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications
    Madeline Vazquez
    Department of Pathology, Weill Medical College of Cornell University, New York, NY 10065, United States
    Lung Cancer 64:148-54. 2009
    ....
  25. ncbi Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia
    Esther S Choi
    Department of Pathology, University of Michigan Medical School, Rm 5216B, Med Sci I, 1301 Catherine Rd, Ann Arbor, MI 48109 0602, USA
    Am J Respir Crit Care Med 170:508-15. 2004
    ....
  26. ncbi Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience
    Inderpal S Sarkaria
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Thorac Surg 92:1180-6; discussion 1186-7. 2011
    ..Pulmonary large cell neuroendocrine carcinomas (LCNEC) are aggressive neoplasms with poor prognosis. The role of neoadjuvant and adjuvant therapies in these tumors remains uncertain...
  27. ncbi FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3598-605. 2012
    ....
  28. ncbi Predicting pulmonary adenocarcinoma outcome based on a cytology grading system
    Carlie S Sigel
    1Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York, USA
    Cancer Cytopathol 120:35-43. 2012
    ..Therefore, we evaluated cytomorphologic features of previously histologically graded AD to identify features of potential prognostic significance...
  29. ncbi Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1348-59. 2011
    ..This simple algorithm achieves excellent accuracy in small specimens while conserving the tissue for potential predictive marker testing, which is now an essential consideration in advanced lung cancer specimens...
  30. ncbi A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors
    Gabriel Sica
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 34:1155-62. 2010
    ..65 (95% confidence interval 0.57-0.73). Therefore, this scoring system provides valuable information in discriminating patients with different risk of disease-recurrence in a highly homogeneous population of patients with stage I cancer...
  31. ncbi Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients
    Kei Suzuki
    Division of Thoracic Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Immunol Immunother 60:1721-8. 2011
    ....
  32. ncbi Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies
    Mark L Kayton
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 5:1764-71. 2010
    ..Herein, we present clinical, histopathologic, and molecular data on eight such cases...
  33. ncbi Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group
    Aliya N Husain
    Department of Pathology, University of Chicago, Chicago, IL 60631, USA
    Arch Pathol Lab Med 133:1317-31. 2009
    ..Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose...
  34. ncbi Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas
    Nicolas Girard
    Human Oncology and Pathogenesis Program HOPP, Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 15:6790-9. 2009
    ..However, whether the underlying biology of these tumors warrants such clustering is unclear, and the optimum treatment of either entity is unknown...
  35. ncbi Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
    ..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice...
  36. ncbi Pathologic findings of lung tumors diagnosed on baseline CT screening
    Douglas B Flieder
    Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Am J Surg Pathol 30:606-13. 2006
    ..This report describes the pathologic findings of the resected cases. Histopathologic distinctions among atypical adenomatous hyperplasia, bronchioloalveolar carcinomas, and invasive adenocarcinoma are described in detail...
  37. ncbi Prognostic immune markers in non-small cell lung cancer
    Kei Suzuki
    Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:5247-56. 2011
    ..This first comprehensive review of prognostic immune markers provides a foundation for further investigating immune responses in NSCLC...
  38. ncbi Aspiration cytomorphology of fetal adenocarcinoma of the lung
    Kim R Geisinger
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Am J Clin Pathol 134:894-902. 2010
    ....
  39. ncbi Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 7:1400-5. 2012
    ..We sought to determine the effect of perioperative chemotherapy in patients with completely resected sarcomatoid carcinomas of the lung...
  40. ncbi Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma
    Kyuichi Kadota
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:896-904. 2011
    ..We sought to investigate whether histologic subtyping can prognostically stratify patients with epithelioid DMPM...
  41. ncbi The 2004 World Health Organization classification of lung tumors
    Mary Beth Beasley
    Providence Portland Medical Center, Department of Pathology, Portland, OR, USA
    Semin Roentgenol 40:90-7. 2005
  42. ncbi Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
    Sizhi Paul Gao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:3846-56. 2007
    ..Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment...
  43. ncbi Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  44. ncbi Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchymal sparing resection
    Inderpal S Sarkaria
    Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Cardiothorac Surg 6:27. 2011
    ..Although classified as low-grade neoplasms, these tumors have a significant rate of recurrence and distant metastasis...
  45. ncbi Feasibility of multimodality therapy including extended resections in stage IVA thymoma
    James Huang
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Cardiovasc Surg 134:1477-83; discussion 1483-4. 2007
    ..We reviewed our experience with multimodality treatment for Masaoka stage IVA thymomas for feasibility and outcomes...
  46. ncbi Transdiaphragmatic amyloidoma
    Daniel J Rosen
    Department of Thoracic Surgery, St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    Ann Thorac Surg 86:310-2. 2008
    ..Clinical suspicion of echinococcal cyst led to treatment via en bloc excision rather than attempting tissue biopsy for diagnosis. Complete resection of the isolated pulmonary amyloidoma was achieved with no evidence of recurrence...
  47. ncbi Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers
    Nicolas Girard
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:5184-90. 2009
    ..Decisions are currently made using the Martini and Melamed criteria, which are mostly based on tumor location and histologic type. New genomic tools could improve the ability to assess tumor clonality...
  48. ncbi Pathologic characteristics of drug-induced lung disease
    Douglas B Flieder
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medical Center, Starr 1015, 525 East 68th Street, New York, NY 10021, USA
    Clin Chest Med 25:37-45. 2004
    ..The latter information is helpful in making the diagnosis of drug toxicity as well as guiding the optimal management of the patient...
  49. ncbi Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer
    Akihiko Yoshizawa
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:240-8. 2010
    ..This study explored expression of eIF4E and its relationship with the PTEN/AKT and RAS/MEK/ERK pathways in non-small cell lung carcinoma (NSCLC)...
  50. ncbi Endotracheal myoepithelioma
    Mastian Chand
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York Hospital Queens, New York Presbyterian Hospital Weill Cornell Medical College, New York, NY, USA
    Chest 140:242-4. 2011
    ..Myoepitheliomas should be considered in the diagnosis of any pulmonary nodule...
  51. ncbi Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia
    Claudia Jakubzick
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0602, USA
    Am J Pathol 164:1989-2001. 2004
    ....
  52. ncbi Localized malignant mesothelioma
    Timothy Craig Allen
    Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    Am J Surg Pathol 29:866-73. 2005
    ..Localized malignant mesotheliomas should be separated from diffuse malignant mesotheliomas because of their localized presentation, quite different biologic behavior, and far better prognosis...
  53. ncbi The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung
    Mary Beth Beasley
    Department of Pathology, Tulane University, New Orleans, LA, USA
    Hum Pathol 34:136-42. 2003
    ..The specific profile of the Rb pathway parameters might provide specific therapeutic targets in neuroendocrine lung tumors...
  54. ncbi Case report: Lung disease in World Trade Center responders exposed to dust and smoke: carbon nanotubes found in the lungs of World Trade Center patients and dust samples
    Maoxin Wu
    Department of Pathology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Environ Health Perspect 118:499-504. 2010
    ..Between 60,000 and 70,000 responders were exposed. Many reported adverse health effects...
  55. ncbi Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma
    Justine A Barletta
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Cell Mol Med 13:1977-86. 2009
    ..Patients with no TTF-1 expression or TTF-1 expression and TTF-1 gene amplification tend to have a significantly worse prognosis than patients with TTF-1 expression and no TTF-1 gene amplification...
  56. ncbi Pulmonary neuroendocrine tumors: What (little) do we know?
    Lin Chi Chen
    Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Natl Compr Canc Netw 4:623-30. 2006
    ..This article discusses the current understanding of the epidemiology, pathologic characteristics, treatment, and prognosis of this spectrum of diseases...
  57. ncbi Sarcomatoid neoplasms of the lung and pleura
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Arch Pathol Lab Med 134:1645-58. 2010
    ....
  58. ncbi Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections
    James R Gill
    New York City Office of Chief Medical Examiner and Department of Forensic Medicine, New York University School of Medicine, NY, USA
    Arch Pathol Lab Med 134:235-43. 2010
    ..In March 2009, a novel swine-origin influenza A/H1N1 virus was identified. After global spread, the World Health Organization in June declared the first influenza pandemic in 41 years...
  59. ncbi Pulmonary lymphangioleiomyomatosis
    Xuchen Zhang
    Department of Pathology, State University of New York, Downstate Medical Center, Brooklyn, 11203, USA
    Arch Pathol Lab Med 134:1823-8. 2010
    ..The TSC1/TSC2 protein-related signaling pathways are involved in the pathogenesis and may provide novel therapeutic targets for lymphangioleiomyomatosis and diseases associated with TSC1 / TSC2 dysfunction...
  60. ncbi Ectopic (mediastinal) parathyroid adenoma with prominent lymphocytic infiltration
    Enzo Fallone
    Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Appl Immunohistochem Mol Morphol 17:82-4. 2009
    ..Immunohistochemical studies were important in making such a diagnosis...
  61. ncbi Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases
    Junya Fukuoka
    Laboratory of Population Genetics, National Cancer Institute, Bethesda, MD, USA
    Am J Surg Pathol 29:948-54. 2005
    ..It is rarely the sole major lung biopsy finding in patients presenting with interstitial lung disease (PBM-ILD). Patients are mostly older women, with mild symptoms and CT findings. Survival appears to be favorable...
  62. ncbi Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis
    Konstantin Shilo
    Armed Forces Institute of Pathology, Department of Pulmonary and Mediastinal Pathology, 6825 16th St NW, Washington, DC 20306, USA
    Arch Pathol Lab Med 131:1555-60. 2007
    ..AMACR serves as a useful marker in establishing a diagnosis of prostatic malignancy; however, limited information is available in regard to its presence in pulmonary neoplasms...
  63. ncbi Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray
    Ping He
    Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, USA
    Hum Pathol 35:1196-209. 2004
    ..Thus, cDNA microarray analysis led to the identification of 2 novel biomarkers that should facilitate molecular diagnosis and further study of pulmonary neuroendocrine tumors...
  64. ncbi Idiopathic interstitial pneumonias: CT features
    David A Lynch
    Department of Radiology, University of Colorado Health Sciences Center, CB A 030, 4200 E Ninth Ave, Denver, CO 80262, USA
    Radiology 236:10-21. 2005
    ..AIP manifests as diffuse lung consolidation and ground-glass opacity. LIP is associated with a CT pattern of ground-glass opacity sometimes associated with perivascular cysts...
  65. ncbi Desmoglein 3 as a prognostic factor in lung cancer
    Junya Fukuoka
    Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Hum Pathol 38:276-83. 2007
    ..8% for desmoglein 3-positive cases (P < .001). Desmoglein 3 status indicated a poor prognosis in lung cancers and portends a more aggressive behavior for atypical carcinoid tumors...
  66. ncbi Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
    Kevin R Flaherty
    Division of Pulmonary and Critical Care Medicine, Department of Radiology, University of Michigan Health System, 3916 Taubman Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0360, USA
    Am J Respir Crit Care Med 170:904-10. 2004
    ..We conclude that dynamic interactions between clinicians, radiologists, and pathologists improve interobserver agreement and diagnostic confidence...
  67. ncbi Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia
    Kevin R Flaherty
    Departments of Radiology and Pathology, Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0360, USA
    Am J Respir Crit Care Med 168:543-8. 2003
    ..47; 95% confidence interval 1.29, 4.73; p = 0.006). We conclude that a 6-month change in forced vital capacity gives additional prognostic information to baseline features for patients with idiopathic interstitial pneumonia...
  68. ncbi The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer
    Ramon Rami-Porta
    Thoracic Surgery Service, Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
    J Thorac Oncol 2:593-602. 2007
    ..To propose changes in the seventh revision of the tumor, node, metastasis (TNM) classification for lung cancer...
  69. ncbi Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease
    Kevin R Flaherty
    Department of Radiology, University of Michigan Health System, Ann Arbor, USA
    Am J Respir Crit Care Med 167:1410-5. 2003
    ..005). We conclude that patients with collagen vascular disease-associated usual interstitial pneumonia have fewer fibroblastic foci and improved survival...
  70. ncbi Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia
    Yangjin Jegal
    Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Pungnap Dong Songpa Ku, Seoul 138 736, South Korea
    Am J Respir Crit Care Med 171:639-44. 2005
    ..Our data confirmed the importance of physiological parameters including short-term change in FVC. However, at the time of diagnosis, histopathology was important for the prediction of prognosis and future change in lung function...
  71. ncbi Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer
    Junya Fukuoka
    Laboratory of Population Genetics, Biometric Research Branch, Center for Bioinformatics, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 10:4314-24. 2004
    ....
  72. ncbi Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium
    Alexander Yu Nikitin
    Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853 6401, USA
    Cancer Res 64:2307-16. 2004
    ....
  73. ncbi Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage
    Mary Beth Beasley
    Department of Pulmonary, Armed Forces Institute of Pathology, Washington, DC 20306, USA
    Arch Pathol Lab Med 126:1064-70. 2002
    ..The need for mechanical ventilation was the only parameter that correlated with prognosis. None of the patients with a subacute clinical course required mechanical ventilation...
  74. ncbi Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens
    Siobhan A Nicholson
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington DC 20306-6000, USA
    Am J Surg Pathol 26:1184-97. 2002
    ..Stage remained the only predictor of prognosis...
  75. ncbi Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?
    Thomas V Colby
    Department of Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Cancer 95:2361-5. 2002
    ....
  76. ncbi Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type
    Ahmedin Jemal
    Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA 30329 4251, USA
    Int J Cancer 105:101-7. 2003
    ....
  77. ncbi A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia
    Kevin K Kim
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI 48109 0642, USA
    Mol Med 9:52-6. 2003
    ..Patients with usual interstitial pneumonia did not show the same relationship with PAl-1 genotype...
  78. ncbi Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia
    Vibha N Lama
    Department of Radiology, University of Michigan Health System, University of Michigan School of Public Health, Ann Arbor, MI 48109-0360, USA
    Am J Respir Crit Care Med 168:1084-90. 2003
    ..We conclude that knowledge of desaturation during a 6-minute walk test adds prognostic information for patients with usual interstitial pneumonia and nonspecific interstitial pneumonia...
  79. ncbi Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis
    Angelo M Taveira-Dasilva
    Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1590, USA
    Am J Respir Crit Care Med 168:1427-31. 2003
    ..We conclude that CPET uncovers the presence of exercise-induced hypoxemia and assists in grading the severity of disease and determining supplemental oxygen requirements in patients with LAM...
  80. ncbi Endobronchial variant of sclerosing hemangioma of the lung: histological and cytological features on endobronchial material
    Mojgan Devouassoux-Shisheboran
    Department of Surgical Pathology, Hopital de la Croix Rousse, Lyon, Cedex 04, France
    Mod Pathol 17:252-7. 2004
    ..Finally, hopefully awareness by clinicians and pathologists that sclerosing hemangioma can present as an endobronchial mass will facilitate diagnosis when this rare event occurs...
  81. ncbi Updated protocol for the examination of specimens from patients with carcinoma of the lung
    Anthony A Gal
    Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, USA
    Arch Pathol Lab Med 127:1304-13. 2003
  82. ncbi A preliminary transcriptome map of non-small cell lung cancer
    Takeshi Fujii
    Laboratory of Population Genetics, Center for Cancer Research, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:3340-6. 2002
    ..Integrating chromosomal mapping information with gene expression profiles may help reveal novel molecular changes associated with human lung cancer...
  83. ncbi Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma
    Louise Burke
    Department of Pathology, Cork University Hospital, Cork, Ireland
    Clin Cancer Res 11:232-41. 2005
    ..We hypothesize that cumulative abnormalities within each and between these pathways would have significant prognostic potential regarding survival...
  84. ncbi Somatic mutations affect key pathways in lung adenocarcinoma
    Li Ding
    The Genome Center at Washington University, Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Nature 455:1069-75. 2008
    ..Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment...
  85. ncbi Exuberant type 2 pneumocyte hyperplasia associated with spontaneous pneumothorax: secondary reactive change mimicking adenocarcinoma
    Konstantin Shilo
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 0001, USA
    Mod Pathol 20:352-6. 2007
    ..Awareness of this severe pneumocyte reaction in the setting of pneumothorax can help to prevent misdiagnosis as malignancy...
  86. ncbi Occult primary parotid gland acinic cell adenocarcinoma presenting with extensive lung metastasis
    Fabio Tavora
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, 6825 16th St NW, Washington, DC 20306, USA
    Arch Pathol Lab Med 131:970-3. 2007
    ..This presentation is unique, showing that peripheral lung tumors of salivary gland type are likely to be metastatic, and careful clinical evaluation is warranted in establishing their primary site of origin...
  87. ncbi Progressive preclinical interstitial lung disease in rheumatoid arthritis
    Bernadette R Gochuico
    Pulmonary Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Dr, MSC 1590, Bethesda, MD 20892 1590, USA
    Arch Intern Med 168:159-66. 2008
    ..The objective of this study was to identify asymptomatic lung disease and potential therapeutic targets in patients having RA and preclinical ILD (RA-ILD)...
  88. ncbi Early interstitial lung disease in familial pulmonary fibrosis
    Ivan O Rosas
    Pulmonary Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1590, USA
    Am J Respir Crit Care Med 176:698-705. 2007
    ..Identification of early, asymptomatic interstitial lung disease (ILD) in populations at risk of developing idiopathic pulmonary fibrosis (IPF) may improve the understanding of the natural history of IPF...
  89. ncbi Absence of human herpesvirus-8 in pulmonary inflammatory myofibroblastic tumor: immunohistochemical and molecular analysis of 20 cases
    Fabio Tavora
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, DC 20306, USA
    Mod Pathol 20:995-9. 2007
    ..This study documents the absence of HHV-8 in pulmonary inflammatory myofibroblastic tumors, suggesting that further investigation is required to clarify the pathogenesis of this lesion...
  90. ncbi Characterizing the cancer genome in lung adenocarcinoma
    Barbara A Weir
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 450:893-8. 2007
    ..More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered...
  91. ncbi Diffuse lung disease in young children: application of a novel classification scheme
    Gail H Deutsch
    Divisions of Pathology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Am J Respir Crit Care Med 176:1120-8. 2007
    ..Considerable confusion exists regarding nomenclature, classification, and management of pediatric diffuse lung diseases due to the relative rarity and differences in the spectrum of disease between adults and young children...
  92. ncbi Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?
    Kevin R Flaherty
    University of Michigan Health System, Ann Arbor, MI 48109 0360, USA
    Am J Respir Crit Care Med 175:1054-60. 2007
    ..Treatment and prognoses of diffuse parenchymal lung diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis among observers is difficult...
  93. ncbi Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening
    Darryl Carter
    Department of Pathology, Yale University School of Medicine, New Haven, CT, United States
    Lung Cancer 56:193-9. 2007
    ..Both baseline and annual repeat cases had a high percentage of invasive carcinomas with comparably high rates of resectability, high rates of node negativity and consequently a high proportion of cases in low stage...
  94. ncbi Pulmonary mucoepidermoid carcinoma with prominent tumor-associated lymphoid proliferation
    Konstantin Shilo
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Am J Surg Pathol 29:407-11. 2005
    ..The dense lymphoplasmacytic infiltrate is similar to that previously described in salivary glands as tumor-associated lymphoid proliferation...
  95. ncbi Pathology of lung cancer
    William D Travis
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, D.C, USA
    Clin Chest Med 23:65-81, viii. 2002
    ....
  96. ncbi Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors
    Junji Tsurutani
    Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 24:306-14. 2006
    ..011 and P = .015, respectively). CONCLUSION: These results suggest that monitoring phosphorylation of Akt at T308 improves the assessment of Akt activation, and show that Akt activation is a poor prognostic factor for all stages of NSCLC...
  97. ncbi Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease
    Christopher J Lettieri
    Pulmonary and Critical Care Medicine, Department of Medicine, Walter Reed Army Medical Center, 6900 Georgia Ave, NW Washington, DC 20307, USA
    Respir Med 99:1425-30. 2005
    ..However, the agreement between general and pulmonary pathologists in histopathologic diagnosis of ILD has not been established...
  98. ncbi Intractable desquamative interstitial pneumonia in a tattooed man
    Toru Arai
    National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan
    Intern Med 45:1055-8. 2006
    ..Steroid therapy with cessation of smoking was partially effective, however his disease worsened again and he died three and a half years after the diagnosis because of respiratory failure...
  99. ncbi Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors
    Yuko Nishio
    Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
    Jpn J Clin Oncol 37:16-22. 2007
    ..Telomeres are important for chromosome structure and function, protecting them against degradation. However, few studies have examined telomeres in pulmonary neuroendocrine (NE) tumors...
  100. ncbi Pulmonary microcystic fibromyxoma: Report of 3 cases
    Konstantin Shilo
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, DC, USA
    Am J Surg Pathol 30:1432-5. 2006
    ....
  101. ncbi Pulmonary light chain deposition disease: report of five cases and review of the literature
    Parul Bhargava
    Department of Pathology at Beth Israel Deaconess Medical Center, Boston MA 02215, USA
    Am J Surg Pathol 31:267-76. 2007
    ..However, when present as nodules, LCDD is more frequently associated with an underlying plasma cell dyscrasia or renal failure than is amyloidosis, and therefore the distinction may be clinically important...